GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company for genome medicines, released six posters for presentation at the ESGCT 31st Annual Congress, which is held from October 22-25, 2024, in Rome, Italy.
Several latest advancements in base editing, DMD, and AAV vector design were featured by poster presentations from GenAssist at ESGCT, which covered a range of cutting-edge research topics:
- Drug metabolism and pharmacokinetics in mice systemically administrated with a base editing drug for Duchenne Muscular Dystrophin (DMD)
- A transformative DMD cytosine base editing drug
- Therapeutic exon skipping through cytidine base editing in DMD mice model
- Potency and off-target evaluation of DMD base editing medicine in vitro
- A Novel AAV Vector Design for Reducing Cross-Packaged ITR Promoter Activity
- Expanding Base Editor Scope with Embedding Strategy
We are eager to showcase our innovative work at this prestigious event.
Stay tuned for updates.
More relevant information is available on the ESGCT website (https://www.esgctcongress.com/programme).
